Monogram Biosciences Inc. (MGRM) Announces New York Medicaid Coverage for Trofile
Monogram Biosciences Inc. (Nasdaq: MGRM) today announced that New York Medicaid has established coverage and reimbursement for the company’s Trofile Assay, a diagnostic used to determine whether or not a patient qualifies for Pfizer's (NYSE: PFE) new HIV anti-viral medication Selzentry. First identified in the United States in 1981, the AIDS epidemic has spread to every corner of the nation. In 1989, targeting New Yorkers who can’t afford medical care, the HIV Primary Care Medicaid Program revamped its reimbursement structure in recognition of the advances in HIV treatment and testing technology. According to Bill Welch, Monogram’s Chief Commercial Officer, the…